Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Addiction. 2013 Nov 11;109(1):128–137. doi: 10.1111/add.12353

Figure 4.

Figure 4

Nicotine replacement therapy (NRT) vs. placebo effect on smoking abstinencea varies with the combined genetic effects of CYP2A6 and CHRNA5

There is a significant interaction between pharmacotherapy (NRT vs. Placebo) and 4 genetic groups (wald=7.44, df=1, p=0.0064). Blue vertical lines are 95% confidence intervals.

a Continued Abstinence for 3 months. b Low vs. risk for CYP2A6 indicates risk for smoking relapse defined by slow vs. fast metabolism. c Low vs. risk for CHRNA5 indicates risk for smoking relapse defined by CHRNA5 (rs16969968, rs680244) (low-risk diplotypes: GG_CC, GG_CT, GA_CC and high-risk diplotypes: GG_TT, GA_CT, AA_ CC).